Natalia Beglova, PhD

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston

2011 Cardiovascular System

Dr. BeglovaMany people with lupus suffer from blood clots. Also called “thromboses,” these clots inside blood vessels interfere with the flow of blood through the body and can cause serious complications. These dangerous clots are more common among people with lupus who have autoimmune antibodies to a particular protein: beta2-glycoprotein I (b2GPI).

With LRI funding, Dr. Beglova will test if a molecule that she has created effectively blocks the activity of this protein in a lupus mouse model.

If this exciting study does in fact uncover a way to interfere with a destructive role of b2GPI, it will open up a whole new avenue for creating medicines to counter damaging and sometimes life-threatening thromboses in lupus.

2014 Publication

Dr. Beglova’s findings of her LRI-funded animal research have shown real promise for treating anti-phospholipid syndrome (APS). She and her colleagues at Harvard Medical School have been investigating the potential of a molecule they call A1-A1, designed as a treatment to specifically block blood clotting caused by antiphospholipid syndrome.
They found that A1-A1 significantly reduced the size of blood clots formed in the blood vessels of lupus mice with APS antibodies.  Importantly the normal blood clotting that is not caused by antibodies, which is essential to prevent bleeding, was unaffected.  The study was recently published in the leading medical journal Blood.
“We are very encouraged by these early results which suggest that A1-A1 can be used as a prototype for the development of new anti-clotting treatments for patients with APS,” said Dr. Beglova.  

Selected Publications

. Epub 2013 Nov 25.
Inhibition of thrombotic properties of persistent autoimmune anti-β2GPI antibodies in the mouse model of antiphospholipid syndrome. Blood. 2014 Feb 13;123(7):1090-7. Kolyada A, Porter A, Beglova N.